- 作者：Michè ; le Kessler ; Paul L ; ais ; Pierre Bataille ; Laurent Yver ; Sé ; bastien Koné ; S ; rine Kraemer ; Georges Brillet ; É ; ric Canivet
- 关键词：Anemia ; Epoetin bê ; ta ; Hemodialysis ; Recommendations ; Hemoglobin
- 刊名：Néphrologie Thérapeutique
- 出版年：2011
- 出版时间：June 2011
- 年：2011
- 卷：7
- 期：3
- 页码：182-187
- 全文大小：293 K
The observational study DiaNE provides a current state of anemia management with Epoetine bêta in hemodialysis patients regarding European recommendations over a 3-year period in France. Patients still treated with Epoetine bêta twelve months after their inclusion in DiaNE were eligible for a 24-month extension phase entitled DiaNE 2. Data regarding 439 patients followed during three years, from M0 to M36, were analyzed. Hemoglobin (Hb) level of the cohort remained over the target value of 11 g/dL during the study (M0: 11.3 ± 1.2 g/dL; M36: 11.8 ± 1.3 g/dL). The anemia management had evolved with European recommendations updates and was in accordance with the last recommended target range (11–12 g/dL) in a third of patients. During the follow-up, the majority of patients (97 % ) had at least one modification of treatment with Epoetine bêta (change in frequency of injections, adjustment of doses) mainly justified by excursion of Hb level out of the target range. However, the median dose of Epoetine bêta was relatively stable. The number of patients with iron treatment remained stable (60 % ). In spite of undertaken efforts, anemia management of hemodialysed patients in France still needs optimization for maintaining Hb level in the recommended target range.